Laboratory Testing for New Patient Establishment of Care
For a new adult patient establishing care in family medicine, order a complete blood count (CBC), comprehensive metabolic panel (CMP), lipid profile, hemoglobin A1C, urinalysis, and thyroid-stimulating hormone (TSH), along with age- and sex-appropriate screening tests for infectious diseases including HIV, hepatitis B and C, and sexually transmitted infections. 1, 2, 3
Core Laboratory Panel
The foundational laboratory workup should include:
Hematologic and Metabolic Assessment
- CBC with differential - screens for anemia, infection, hematologic disorders 1, 2
- Comprehensive metabolic panel including:
Cardiovascular and Metabolic Risk
- Fasting lipid profile (total cholesterol, LDL, HDL, triglycerides) 1, 2, 3
- Hemoglobin A1C - screens for diabetes and prediabetes 1, 3
Additional Screening
- Urinalysis - evaluates for proteinuria, hematuria, glycosuria, and urinary tract disease 1, 2, 4
- TSH - screens for thyroid dysfunction, particularly important in women over 50 and those with type 1 diabetes or dyslipidemia 1, 3
Infectious Disease Screening
Universal Screening
- HIV antibody/antigen testing - recommended for all adults establishing care 5, 6, 7
- Hepatitis B surface antigen and antibodies (anti-HBs, anti-HBc) 5, 6, 7
- Hepatitis C antibody with reflex PCR if positive 5, 6, 7
- Syphilis screening (RPR or VDRL) 5, 6, 7
Risk-Based Screening
- Gonorrhea and chlamydia - for sexually active patients under 25 or those at increased risk 5, 6, 7
- Toxoplasma serology - if immunocompromised or planning pregnancy 6
Age- and Sex-Specific Considerations
Women of Reproductive Age
- Rubella immunity 7
- Varicella immunity (if no history of chickenpox or vaccination) 7
- Cervical cytology (Pap test) as indicated by age and screening history 7
- Pregnancy test if clinically relevant 7
Patients with Specific Risk Factors
Diabetes risk factors (obesity, family history, hypertension):
- Hemoglobin A1C already included above provides superior screening to fasting glucose alone 1
Liver disease risk (alcohol use, obesity, metabolic syndrome):
- Liver function tests already included in CMP
- Consider adding GGT if NAFLD suspected 4
Kidney disease risk (diabetes, hypertension, Black race, family history):
Cardiovascular disease risk:
- Lipid profile already included above
- Consider high-sensitivity CRP in intermediate-risk patients (not routinely recommended) 2
Important Caveats
What NOT to Routinely Order
- CD8 cell counts or CD4:CD8 ratios - not useful for clinical decision-making even in HIV-positive patients 5, 6
- Extensive autoimmune panels - only order if clinical suspicion exists (e.g., anti-mitochondrial antibody, anti-smooth muscle antibody, ANA only if liver disease suspected) 4
- Tumor markers - not appropriate for screening in asymptomatic patients
- Vitamin D - only if specific risk factors present (osteoporosis, malabsorption, chronic kidney disease) 1
Timing Considerations
- Fasting required for lipid profile and glucose (8-12 hours) 1, 3
- Medication review - document use of metformin (check B12), ACE inhibitors/ARBs (monitor potassium), statins (baseline liver function), or other medications affecting lab values 1
Follow-Up Testing Frequency
Once baseline established:
- A1C: every 3 months if diabetic and not at goal; annually if prediabetic or well-controlled 1, 3
- Lipids: annually if on therapy or high-risk; every 3-5 years if normal and low-risk 1
- Renal function: annually if diabetic, hypertensive, or on nephrotoxic medications; more frequently if CKD present 1
- Liver function: annually; more frequently if on hepatotoxic medications 1
Clinical Integration
The laboratory results must be interpreted in context of the complete history and physical examination - isolated abnormal values without clinical correlation can lead to unnecessary workup and patient anxiety 8. For example, a mildly elevated alkaline phosphatase in an asymptomatic patient may simply reflect bone turnover, while the same value in someone with right upper quadrant pain warrants hepatobiliary investigation 4.
Document all results and ensure appropriate follow-up - abnormal findings require either immediate intervention or a clear plan for monitoring and repeat testing 4. Establish systems to track pending results and communicate findings to patients, as failure to follow up on abnormal laboratory values represents a significant medicolegal risk.